Leonteq Securities AG’s Catalyst Pharmaceutical CPRX Stock Holding History

Leonteq Securities AG’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$98.2K	Buy	3,968 +1,707	+75%	+$40.7K	﹤0.01%	738
2025 Q4	$52.8K	Hold	2,261	–	–	﹤0.01%	945
2025 Q3	$44.5K	Sell	2,261 -439	-16%	-$9.03K	﹤0.01%	901
2025 Q2	$58.6K	Sell	2,700 -23	-0.8%	-$543	﹤0.01%	821
2025 Q1	$65.8K	Sell	2,723 -502	-16%	-$11.3K	﹤0.01%	793
2024 Q4	$69.2K	Sell	3,225 -84	-3%	-$1.8K	﹤0.01%	760
2024 Q3	$65.8K	Buy	3,309 +1,266	+62%	+$23.5K	0.01%	706
2024 Q2	$31.6K	Buy	2,043 +98	+5%	+$1.53K	﹤0.01%	849
2024 Q1	$31K	Buy	+1,945	New	+$29.3K	﹤0.01%	858
2022 Q3	–	Sell	-4,000	Closed	-$28K	–	1294
2022 Q2	$28K	Buy	+4,000	New	+$29.3K	﹤0.01%	934
2021 Q4	–	Sell	-4,000	Closed	-$21.2K	–	1272
2021 Q3	$21.2K	Hold	4,000	–	–	﹤0.01%	982
2021 Q2	$23K	Buy	+4,000	New	+$20.6K	﹤0.01%	931

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Leonteq Securities AG's CPRX Position: Q1 2026 in Review

Leonteq Securities AG increased its Catalyst Pharmaceutical (CPRX) stake by 75% in Q1 2026, buying an estimated $40.7K and bringing the position to 3,968 shares worth $98.2K. The position accounts for ﹤0.01% of the portfolio, ranked #738.

Leonteq Securities AG first reported a position in CPRX in Q2 2021 and has held it in 12 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Leonteq Securities AG held 3,968 shares of Catalyst Pharmaceutical worth $98.2K as of Q1 2026.
Leonteq Securities AG bought 1,707 Catalyst Pharmaceutical shares in Q1 2026, an estimated $40.7K.
Catalyst Pharmaceutical made up ﹤0.01% of Leonteq Securities AG's portfolio in Q1 2026, its #738 holding.
Leonteq Securities AG first reported a position in Catalyst Pharmaceutical in Q2 2021 and has held it in 12 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Leonteq Securities AG's 13F filing for Q1 2026, filed 27 Apr 2026.